The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

Sponsor
Zafer Soultan (Other)
Overall Status
Completed
CT.gov ID
NCT01616862
Collaborator
(none)
53
1
18
2.9

Study Details

Study Description

Brief Summary

Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older. The investigators want to learn more about how Pa is passed from person to person, especially to someone with Cystic Fibrosis (CF).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    People with CF (cystic fibrosis) often have lung infections which occur repeatedly or worsen over time. The lung infections are most often caused by bacteria. Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older. The investigators want to learn more about how Pa is passed from person to person, especially to someone with CF. The respiratory secretions of someone colonized with Pa can transmit or pass on the bacterium. The bacterium can be passed through direct contact by two individuals kissing or touching hands. Another way to pass Pa is by indirect contact such as touching an object like an eating utensil or drinking glass that has been used by someone with Pa.

    There are many unanswered questions about Pa lung infections in people with CF. For example, it is not known why some people with CF develop Pa lung infections earlier than others. Nor is it known why it is difficult to eradicate Pa in some children and why some children's condition to deteriorate quicker than other after becoming infected with Pa.

    Biological parents of children with CF are carriers of one CF causing gene mutation. It is also possible that they are carriers of additional, but milder, CF-related gene mutations. It is possible that the carrier status of the parents of CF children place them at risk of acquiring and carrying Pa in their lungs.

    Biological parents of children who have CF will be asked to participate. This study plans to assess the frequency of Pa in biological parents and to correlate the clinical and microbiological status of CF children with PA carrier rates of their parents.

    Parents will be asked to complete questionnaires at one routine, clinic visit, have nasal and throat cultures collected during their child's routine scheduled visit and again 3-4 months later (at another routine visit). The investigators are also asking permission to review the medical records of their child with CF.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    53 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis
    Study Start Date :
    Feb 1, 2012
    Actual Primary Completion Date :
    Jun 1, 2013
    Actual Study Completion Date :
    Aug 1, 2013

    Arms and Interventions

    Arm Intervention/Treatment
    Parents of PA positive CF children

    parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa

    parents of Pa negative CF children

    parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa

    Outcome Measures

    Primary Outcome Measures

    1. Primary objective: the incidence of Pseudomonas aeruginosa colonization in the upper respiratory tract of parents of children with CF. [6 months]

      Collection of nasal and oropharyngeal swabs will be obtained from parents living with patients at enrollment and after 3 months.

    2. Primary objective: the incidence of Pseudomonas aeruginosa colonization in the upper respiratory tract of parents of children with CF. [Day 0]

      Collection of nasal and oropharyngeal swabs will be obtained from parents living with patients at enrollment and after 3 months.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    5 Years to 19 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Biological parents of children with CF will be invited to participate and included if their children meet the following criteria:

    • children's age is more than 5 years and less than 20 years of age.

    Exclusion Criteria:
    • Biological parents of children younger than 5 years of age or older than 20 years of age.

    • Step parents.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 SUNY Upstate Medical University Syracuse New York United States 13210

    Sponsors and Collaborators

    • Zafer Soultan

    Investigators

    • Principal Investigator: Zafer Soultan, MD, State University of New York - Upstate Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Zafer Soultan, Associate professor, State University of New York - Upstate Medical University
    ClinicalTrials.gov Identifier:
    NCT01616862
    Other Study ID Numbers:
    • 274342
    First Posted:
    Jun 12, 2012
    Last Update Posted:
    Jun 2, 2015
    Last Verified:
    May 1, 2015
    Keywords provided by Zafer Soultan, Associate professor, State University of New York - Upstate Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 2, 2015